Therapy News and Research

RSS

Researchers discover why multiple myeloma recurs after initially effective treatment

Researchers have discovered why multiple myeloma, a difficult to cure cancer of the bone marrow, frequently recurs after an initially effective treatment that can keep the disease at bay for up to several years.

19 Sep 2013

Guidance for medication in bipolar depression published

Solid evidence to guide the use of antidepressants in patients with bipolar disorder is “remarkably limited,” says the International Society for Bipolar Disorders Task Force.

18 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout is the most common form of inflammatory arthritis that affects adults. It's a disease caused by the presence of uric acid crystals in and around the joints. It's a disease that's becoming more and more common. It probably has doubled in its prevalence worldwide over the past twenty to thirty years.

18 Sep 2013

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo.

18 Sep 2013

UAB paper suggests that physical activity, exercise important for healthy aging

A clinical review from geriatricians at the University of Alabama at Birmingham suggests that mobility limitations are a litmus test for healthy aging and urges primary care physicians to take a more aggressive role in ascertaining the mobility of their older patients.

18 Sep 2013

AAPM commends FDA’s move to introduce labeling changes on ER/LA opioids

The physicians of the American Academy of Pain Medicine (AAPM) hailed long-awaited labeling changes and other steps taken by the U.S. Food and Drug Administration (FDA) last week to enhance safety in the prescribing of extended-release and long-acting (ER/LA) opioids.

18 Sep 2013

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

Boehringer Ingelheim and Eli Lilly and Company today announced they will feature five oral and 12 poster presentations for linagliptin and the investigational compound empagliflozin* at the 49th Annual Meeting of the European Association for the Study of Diabetes (EASD) which will take place in Barcelona, from 23 – 27 September. The presentations will add to the already existing body of data on safety and efficacy of these two compounds.

18 Sep 2013

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

GW Pharmaceuticals plc announced today it has commenced a Phase 1 clinical trial of product candidate GWP42006 for the treatment of epilepsy.

18 Sep 2013

Study proves advantages of immediate surgery for patients with acute cholecystitis

Should surgery be performed immediately, or is it better to first administer antibiotics and then perform surgery? A study led by Heidelberg University Hospital Department of Surgery has demonstrated that patients suffering from acute cholecystitis should be operated on immediately. There are no advantages to delaying surgery until antibiotic therapy has been administered for several weeks. After undergoing surgery performed within 24 hours of diagnosis, the patients have fewer complications, are back on their feet earlier, and can leave the hospital more quickly.

18 Sep 2013

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

Researchers from the University of Chicago have been awarded a five-year, $1.5 million grant from the National Institutes of Health to develop stimulated dendritic cell-derived exosomes that show remarkable promise as a treatment for multiple sclerosis and other neurological diseases involving loss of myelin, the insulation around nerve fibers.

18 Sep 2013

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

SignaBlok, Inc., a Massachusetts-based biopharmaceutical company, today announced the successful in vivo proof of concept data that demonstrate that the company's novel mechanism-based, first-in-class peptide inhibitor of TREM-1 effectively suppresses cancer progression in mouse models of lung cancer and dramatically improves survival in septic mice.

18 Sep 2013

NHCS researchers discover potential cure for long QT syndrome 2

The National Heart Centre Singapore research team has successfully and completely reversed the effects of the hERG (human ether-a-go-go-related gene) mutation in long QT syndrome 2 in patient-specific heart cells, scoring a world's first.

18 Sep 2013

Study: Mesenchymal stem cell transplantation may help treat stress urinary incontinence

Vaginal delivery presents the possibility of injury for mothers that can lead to "stress urinary incontinence", a condition affecting from four to 35 percent of women who have had babies via vaginal delivery. Many current treatments, such as physiotherapy and surgery, are not very effective.

18 Sep 2013

Cleveland Clinic creates spin-off company to develop vaccine for preventing breast cancer

Cleveland Clinic Innovations has created a spin-off company to develop a preventive breast cancer vaccine based on research from Cleveland Clinic's Lerner Research Institute.

18 Sep 2013

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

UCF College of Medicine professor Dr. Saleh Naser soon will participate in a clinical trial to test whether a new antibiotic therapy acquired by RedHill Biopharma can be used to treat Crohn's disease patients.

18 Sep 2013

Abnormalities in brain axons predispose people to chronic back pain after injury

Abnormalities in the structure of the brain predispose people to develop chronic pain after a lower back injury, according to new Northwestern Medicine- research. The findings could lead to changes in the way physicians treat patients' pain.

18 Sep 2013

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Boehringer Ingelheim Pharmaceuticals, Inc. today announced the FDA has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase, being evaluated for the treatment of patients aged 65 or older with previously untreated acute myeloid leukemia, ineligible for intensive remission induction therapy.

17 Sep 2013

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Regado Biosciences, Inc., a biopharmaceutical company focused on the discovery and development of novel, first-in-class, actively controllable antithrombotic drug systems for acute and sub-acute cardiovascular indications, today announced the enrollment of the first patient in its REGULATE-PCI clinical trial.

17 Sep 2013

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Acacia Pharma, a pharmaceutical company specialising in the development of drugs for supportive care, announces the initiation of two pivotal Phase 3 studies of APD421 in the prevention of post-operative nausea & vomiting (PONV).

17 Sep 2013

Therapy News and Research

Researchers discover why multiple myeloma recurs after initially effective treatment

Guidance for medication in bipolar depression published

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

UAB paper suggests that physical activity, exercise important for healthy aging

AAPM commends FDA’s move to introduce labeling changes on ER/LA opioids

Efficacy and safety data on linagliptin and investigational compound empagliflozin* in various diabetes subpopulations presented by Boehringer Ingelheim and Eli Lilly and Company

GW Pharmaceuticals starts GWP42006 Phase 1 clinical trial for epilepsy treatment

Study proves advantages of immediate surgery for patients with acute cholecystitis

University of Chicago researchers awarded NIH grant to develop novel multiple sclerosis treatment

SignaBlok's novel peptide inhibitor of TREM-1 suppresses cancer progression

NHCS researchers discover potential cure for long QT syndrome 2

Study: Mesenchymal stem cell transplantation may help treat stress urinary incontinence

Cleveland Clinic creates spin-off company to develop vaccine for preventing breast cancer

RedHill Biopharma to initiate phase III trial of RHB 104 in Crohn's disease patients

Abnormalities in brain axons predispose people to chronic back pain after injury

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Regado Biosciences announces enrollment of first patient in REGULATE-PCI clinical trial

Acacia Pharma initiates two pivotal Phase 3 studies of APD421 in prevention of PONV

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News